KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Research & Development: 2009-2025

Historic Research & Development for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $977.7 million.

  • Vertex Pharmaceuticals' Research & Development rose 11.62% to $977.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 13.84%. This contributed to the annual value of $3.6 billion for FY2024, which is 14.78% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Research & Development of $977.7 million as of Q3 2025, which was down 0.07% from $978.4 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Research & Development high stood at $998.7 million for Q4 2024, and its period low was $448.7 million during Q2 2021.
  • Over the past 3 years, Vertex Pharmaceuticals' median Research & Development value was $875.9 million (recorded in 2024), while the average stood at $884.5 million.
  • In the last 5 years, Vertex Pharmaceuticals' Research & Development fell by 5.37% in 2021 and then skyrocketed by 38.12% in 2022.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Research & Development stood at $567.8 million in 2021, then climbed by 22.24% to $694.1 million in 2022, then grew by 18.80% to $824.6 million in 2023, then grew by 21.11% to $998.7 million in 2024, then rose by 11.62% to $977.7 million in 2025.
  • Its Research & Development was $977.7 million in Q3 2025, compared to $978.4 million in Q2 2025 and $979.7 million in Q1 2025.